XML 68 R50.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of equity method investments (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2023
Schedule of Equity Method Investments [Line Items]          
Equity attributable to investee $ 228,449 $ 291,117      
Revenues 343,032   $ 432,090    
Net (loss) income attributable to investees $ (49,165)   $ 17,155    
Five Investments          
Schedule of Equity Method Investments [Line Items]          
Current assets   47,356     $ 51,588
Noncurrent assets   266,995     269,809
Current liabilities   9,524     8,594
Noncurrent liabilities   621     760
Noncontrolling interest   2,826     2,876
Revenues   33,966   $ 27,971  
Cost of revenues   19,069   16,387  
Five Investments | Investee          
Schedule of Equity Method Investments [Line Items]          
Equity attributable to investee   301,380     309,167
Net (loss) income attributable to investees   15,152   11,808  
FRG          
Schedule of Equity Method Investments [Line Items]          
Current assets   961,787     1,219,682
Noncurrent assets   3,131,506     3,142,660
Current liabilities   720,510     749,894
Noncurrent liabilities   2,640,805     2,695,445
Revenues   806,229      
Cost of revenues   499,679      
Loss from continuing operations   (1,175)      
FRG | Investee          
Schedule of Equity Method Investments [Line Items]          
Equity attributable to investee   731,978     917,003
Net (loss) income attributable to investees   (169,583)      
B&W          
Schedule of Equity Method Investments [Line Items]          
Current assets   497,593     542,300
Noncurrent assets   278,105     294,979
Current liabilities   350,197     393,539
Noncurrent liabilities   625,851     585,430
Noncontrolling interest   611     626
Revenues   227,167   236,424  
Cost of revenues   171,552   182,760  
Loss from continuing operations   (54,266)   (2,289)  
Net (loss) income attributable to investees   (62,724)   5,660  
B&W | Investee          
Schedule of Equity Method Investments [Line Items]          
Equity attributable to investee   (200,961)     (142,316)
Net (loss) income attributable to investees   (66,454)   2,021  
Synchronoss Technologies, Inc.          
Schedule of Equity Method Investments [Line Items]          
Current assets   82,002     85,903
Noncurrent assets   228,335     275,304
Current liabilities   47,697     74,528
Noncurrent liabilities   164,706     166,673
Revenues   41,402   41,252  
Cost of revenues   10,292   11,999  
Synchronoss Technologies, Inc. | Investee          
Schedule of Equity Method Investments [Line Items]          
Equity attributable to investee   97,934     120,006
Net (loss) income attributable to investees   (35,001)   (15,927)  
Other Equity Investments          
Schedule of Equity Method Investments [Line Items]          
Current assets   279,810     281,610
Noncurrent assets   622,632     627,858
Current liabilities   185,925     150,114
Noncurrent liabilities   236,829     277,638
Preferred stock   4,500     4,500
Revenues   170,034   37,924  
Cost of revenues   145,288   33,062  
Other Equity Investments | Investee          
Schedule of Equity Method Investments [Line Items]          
Equity attributable to investee   475,188     $ 477,216
Net (loss) income attributable to investees   $ (852)   $ (13,613)